This article is more than 5 years old. Information may no longer be current.
FDA accepts New Drug Application for binge eating disorder treatment
Click Here to Manage Email Alerts
The FDA has accepted Sunovion Pharmaceuticals’ New Drug Application for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, for the treatment of patients with moderate-to-severe binge eating disorder, according to a press release.
Dasotraline, an investigational, once-daily medication with a pharmacokinetic profile characterized by an extended half-life, has shown significant efficacy for the treatment of moderate-to-severe binge eating disorder in two 12-week, randomized, placebo-controlled studies, known as SEP360-221 and SEP360-321, according to the release. In addition, dasotraline was generally well-tolerated in clinical studies, including a long-term safety study, which examined patients with binge eating disorder for up to 1 year.
The Prescription Drug User Fee Act (PDUFA) date is May 14, 2020, according to the release.
“Binge eating disorder is a serious mental health condition for which limited treatment options exist. The disorder is often seen in association with other behavioral conditions such as depression, substance abuse and post-traumatic stress disorder, and it is often under-diagnosed and under-treated,” Antony Loebel, MD, president and CEO at Sunovion, said in the release. “We are confident in the value dasotraline has shown in clinical trials to people living with [binge-eating disorder] and look forward to working with the FDA to advance this novel treatment option.”